Diabetes Vaccine Market: Deep Analysis by Production Overview and Insights 2018-2026

Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses.

Download The PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1367

Diabetes vaccine is being developed to strengthen the body’s response against enterovirus called coxsackievirus B1, wherein it senses enterovirus and produces immune response to destroy it. It destroys the insulin producing beta cell in pancreas, which is linked with type 1 diabetes. Though currently there is no approved diabetes vaccine available, however, key players are focusing on research to develop such vaccines by targeting various mechanisms that triggers the autoimmune response.

High global prevalence of type 1 diabetes is expected to aid in growth of the market over the forecast period

High global prevalence and incidence of type 1 diabetes is, inadvertently expected to create a conducive environment for growth of the diabetes vaccine market. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide by end of 2017. Of this, one million people (children and adolescents below 20 years of age) are suffering from type 1 diabetes, with around 150,000 new cases reported each year.

Furthermore, patients suffering from type 1 diabetes need constant monitoring and may also require insulin externally, which has to be taken intramuscularly every day. This becomes difficult for children. Cost associated with insulin therapy is also relatively high. These are expected to be factors supporting growth of the market.

Developments in the diabetes vaccine market

Imcys— a Belgium-based biotech company— announced plans to commence its clinical trial in 2018 for new diabetes vaccine to treat type 1 diabetes. It uses modified peptides called imotopes, which spurs specific type of immune cell to kill immune cells that work on the insulin producing beta cells.

Moreover, in 2017, Massachusetts General Hospital Immunobiology Laboratory presented findings of clinical trial at 75th Scientific Sessions of the American Diabetes Association, related to use of BCG vaccine to treat autoimmune response in type 1 diabetes. BCG vaccine could induce a permanent gene expression that restores regulatory T cells, thereby preventing the immune system attack, which is observed in type 1 diabetes. It is currently under phase two clinical trial.

Discuss Your Queries With Our Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1367

North America market is expected to exhibit high growth, followed by Europe and Asia Pacific markets over the forecast period

North America is expected to exhibit high growth in the global diabetes vaccine market over the forecast period. This is owing to increasing incidence of diabetes and high resultant healthcare burden in the U.S. For instance, according to IDF, 17,100 new cases were detected in 2017 in the U.S. Around US$ 377 billion was spent over entire diabetes disease range, which accounts for about 52% of the total healthcare expenditure on diabetes worldwide. Significant part of which goes into maintaining constant blood sugar in type 1 by use of insulin.

According to statistics released by American Diabetes Association, in 2017, around 193,000 people under 20 years of age in the U.S. were estimated to be diagnosed with diabetes, which accounts for 0.24% of this population. This inadvertently, is expected to create a conducive environment for growth of the market. U.S. has maximum number of children and adolescent(under age 20) with Type 1 diabetes at range of 1,69,600 in 2017,this is followed by India with highest cases type 1 diabetes after the U.S at range of 1,28,500 as reported by IDF.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.